IPO Guru
Bajaj
Closed Mainboard

Sahajanand Medical Technologies IPO

Sahajanand Medical Technologies IPO — date, price band, lot size & details 2026

Sahajanand Medical Technologies listed on 23 Oct 2026 at ₹371.15, 7.9% above the ₹344 issue price.

Sahajanand Medical Technologies makes Class III heart devices such as drug-eluting stents, TAVI valves and occluders. Total income was Rs 1,218.73 crore in FY2026 and restated profit after tax was Rs 69.08 crore.

Stock price

Sahajanand Medical Technologies is listed — here is the live share price.

Loading market data…
Abhishek Vohera, Founder of IPO Guru Researched & reviewed by Abhishek Vohera, Founder, IPO Guru Last updated Figures sourced from the RHP, BSE & NSE

Timetable

Key dates from opening to listing. Today is 17 November.

Key dates Listed
  1. Open 15 Oct 2026
  2. Close 19 Oct 2026
  3. Allotment 21 Oct 2026
  4. Refund/credit 22 Oct 2026
  5. Listing 23 Oct 2026

Latest news

Our news coverage of Sahajanand Medical Technologies, newest first.

All IPO news →

Issue summary

The terms of the offer, as filed.

IPO Dates 15 to 19 Oct, 2026
Price Band ₹327 – ₹344
Face Value ₹1
Lot Size 43 Shares
Issue Size ₹475.48 Cr
Sale Type OFS only
Listing On BSE, NSE
Registrar MUFG Intime India Private Limited
Min Investment ₹ 14,792
Reservation
QIB 50%
NII 15%
Retail 35%
Employee 1.81%

Share of the offer set aside for each investor category, as stated in the offer document.

What will it cost me?

Bidding is in multiples of 43 shares at the ₹344 cut-off. Drag to size your application.

shares
1 lot lots
If it lists at today's grey market premium of ₹17
on
Grey market premium is an unofficial, unregulated indicator. It is not a forecast.
Application Lots Shares Amount
Retail (min) 1 43 ₹14,792
Retail (max) 13 559 ₹1,92,296
S-HNI (min) 14 602 ₹2,07,088
S-HNI (max) 67 2,881 ₹9,91,064
B-HNI (min) 68 2,924 ₹10,05,856

Strengths & risks

Drawn from the offer document — the case for and against, side by side.

Strengths · 6

  • 01Total income grew from Rs 908.59 crore in FY2024 to Rs 1,035.96 crore in FY2025 and Rs 1,218.73 crore in FY2026.
  • 02Profit after tax moved from a loss of Rs 7.35 crore in FY2024 to Rs 25.15 crore in FY2025 and Rs 69.08 crore in FY2026.
  • 03EBITDA rose from Rs 110.05 crore in FY2024 to Rs 170.66 crore in FY2026, with an EBITDA margin of 13.81%.
  • 04Net worth rose from Rs 526.30 crore in FY2024 to Rs 616.05 crore in FY2026, and Rs 631.72 crore on 30 June 2026.
  • 05The company holds 102 granted patents and its products are backed by 72 clinical studies.
  • 06Products are sold in over 76 countries, with direct operations in Germany, Spain, France and the UK.

Risks · 7

  • 01The whole issue is an offer for sale of Rs 475.48 crore. The company receives no money from it, so none of the proceeds fund growth or reduce borrowing.
  • 02At the upper band of Rs 344 the issue is priced at 57.91 times post issue EPS of Rs 5.94. One lot is 43 shares, about Rs 14,792 at the upper band.
  • 03RoNW is 2.31% and RoCE is 3.16%, which are low for the size of the business, and FY2024 was a loss year.
  • 04Total borrowing rose from Rs 175.27 crore in FY2024 to Rs 269.53 crore in FY2026 and Rs 320.63 crore on 30 June 2026.
  • 05Promoter holding falls from 40.82% before the issue to 36.2% after it.
  • 06The business depends on regulated Class III devices, so product approvals, clinical results and tenders can affect revenue.
  • 07Sales are spread over many countries, so currency moves and local rules can affect results.

Three years of numbers

All figures in ₹ crore, as reported in the Sahajanand Medical Technologies offer document.

Total income
354.33
1,036
1,219
354
31 Mar 202531 Mar 202630 Jun 2026
Profit after tax
15.09
25
69
15
31 Mar 202531 Mar 202630 Jun 2026
EBITDA
48.58
128
171
49
31 Mar 202531 Mar 202630 Jun 2026
Borrowing vs net worth
320.63 / 631.72
31 Mar 202531 Mar 202630 Jun 2026
Borrowing Net worth
Metric 30 Jun 2026 31 Mar 2026 31 Mar 2025 31 Mar 2024
Assets 1,309.00 1,276.43 1,094.90 970.58
Total Income 354.33 1,218.73 1,035.96 908.59
Profit After Tax 15.09 69.08 25.15 -7.35
EBITDA 48.58 170.66 128.02 110.05
NET Worth 631.72 616.05 545.23 526.30
Reserves and Surplus 706.86 692.48 580.71 556.57
Total Borrowing 320.63 269.53 224.96 175.27

See how this IPO compares — view listing performance of all mainboard IPOs.

Valuation & key ratios

Ratios are for the latest full financial year reported in the Sahajanand Medical Technologies RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.

P/E Ratio
57.91
EPS (₹)
5.94
RoE
2.07%
RoCE
3.16%
RoNW
2.31%
PAT Margin
4.29%
EBITDA Margin
13.81%
Debt / Equity
0.33
NAV (₹)
64.35

Sahajanand Medical Technologies IPO Valuation

How the issue prices the company before and after the fresh shares are created.

Valuation Metric Pre-Issue Post-Issue
EPS (₹) ₹6.80 ₹5.94
P/E Ratio (x) 50.59 57.91
Market Cap at Offer Price (₹ Cr) ₹763.38 ₹3,496.65

Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹344 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.

Where the money goes

How the company intends to use the proceeds of the issue.

Offer for sale by the selling shareholders. The company receives no proceeds from the offer Not stated

Sahajanand Medical Technologies IPO Anchor Investors

10 anchor investors across 8 fund houses committed ₹140.06 Cr a day before the issue opened.

Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.

About the company

Sahajanand Medical Technologies Ltd. was founded in 2001 by Dhirajlal Kotadia. It is a medical device company focused on Class III and Class C/D devices, mainly for vascular and structural heart intervention. It was the first company in the world to get CE certification for a drug-eluting stent with a biodegradable polymer, called Infinnium.

The products fall in three groups. Vascular intervention covers coronary stents and balloons. Structural heart covers TAVI and occluders. Other products include renal stents, peripheral drug-coated balloons and some trading products.

The company has two R&D centres, one in India and one in Thailand, with 102 professionals. It holds 102 granted patents globally and has 71 pending applications. Key brands are Supraflex Cruz, Hydra (TAVI) and Cocoon (occluders), backed by 72 clinical studies and sold in over 76 countries. It sells directly in Germany, Spain, France and the UK, uses a hybrid model in India and distributors in markets such as Italy. As of 31 March 2025 it had 1,458 full-time staff, 24 consultants and 818 contract personnel.

Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.

Promoters
Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust
Promoter holding
40.82% → 36.2%
Pre-issue → post-issue
Registered office
Sahajanand Estate, Wakharia Wadi, NR. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat, 395004
022 49564000

The bankers & the filings

Who is running the book, and the documents this page is built from.

Book-running lead manager
HSBC Securities & Capital Markets (India) Pvt. Ltd. View track record →
Book-running lead manager
Nuvama Wealth Management Ltd. View track record →
Book-running lead manager
Motilal Oswal Investment Advisors View track record →
Book-running lead manager
Avendus Capital View track record →
Red Herring Prospectus
SEBI filing
Final offer document — price band, financials and risk factors. This page is built from it.
Open the RHP

Sahajanand Medical Technologies IPO Documents

Read the filings this page is built from.

Lead Manager Track Record

How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.

Listed in Profit 76.5% 26 of 34 listed
Avg Listing Gain +12.8% across 34 issues
Listed Below Issue 8 of 34 listed

Best listing: Gujarat State Petronet (+72.2%). Weakest: Nuvoco Vistas Corporation (-14.9%).

Nuvama Wealth Management Ltd.

42 issues handled
Listed in Profit 69% 29 of 42 listed
Avg Listing Gain +11.9% across 42 issues
Listed Below Issue 13 of 42 listed

Best listing: Gandhar Oil Refinery (India) (+76.3%). Weakest: ACME Solar Holdings (-13.1%).

Listed in Profit 69.2% 54 of 78 listed
Avg Listing Gain +15% across 78 issues
Listed Below Issue 24 of 78 listed

Best listing: G R Infraprojects (+105.0%). Weakest: R K Swamy (-13.2%).

Avendus Capital

11 issues handled
Listed in Profit 63.6% 7 of 11 listed
Avg Listing Gain +7.4% across 11 issues
Listed Below Issue 4 of 11 listed

Best listing: FirstCry (+40.0%). Weakest: Innoventive Industries (-4.3%).

Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.

Company contact

Company
Sahajanand Medical Technologies
Email

Frequently asked

What is the GMP of Sahajanand Medical Technologies?

The current Grey Market Premium is ₹17, or 4.94% over the issue price.

What is the Sahajanand Medical Technologies IPO price band?

₹327 to ₹344, on a face value of ₹1.

When is the allotment?

The basis of allotment is 21 October 2026, with listing on 23 October 2026.

How do I check allotment status?

On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.

Sahajanand Medical Technologies IPO

Every number here traces back to a filing.

IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.

Join the WhatsApp channel All mainboard IPOs

Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.

GMP
₹17
Subscribed
14.2×
Min bid
₹14,792
Size my application
Advertisement